Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 14/20 | 0.59 |
| ▸ | CES1 | P23141 | 13/20 | 0.59 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10747173 | 0.79 | CES2 (0.47) | CES2CES1PRMT1TSHRALDH1A1 | |
| SCHEMBL28946791 | 0.78 | CES2 (0.46) | CES2CES1PRMT1CA2CA4 | |
| SCHEMBL946802 | 0.76 | CES1 (0.52) | CES2CES1PRMT1CA2CA4 | |
| Benzil SCHEMBL27888964 | 0.76 | CES1 (0.96) | CES2CES1CA2TSHRALDH1A1 | |
| SCHEMBL7260785 | 0.75 | PRMT1 (0.54) | CES2CES1PRMT1CA2CA4 | |
| SCHEMBL14935500 | 0.75 | PRMT1 (0.54) | CES2CES1PRMT1CA2CA4 | |
| SCHEMBL10995027 | 0.75 | PRMT1 (0.54) | CES2CES1PRMT1CA2CA4 | |
| SCHEMBL27447659 | 0.75 | CES2 (0.52) | CES2CES1PRMT1CA2CA4 | |
| Benzil SCHEMBL7142843 | 0.74 | CES2 (1.00) | CES2CES1CA2CA4DAO | |
| Benzil SCHEMBL9517636 | 0.74 | CES2 (1.00) | CES2CES1CA2CA4DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021006346-A1 | METHOD FOR PROMOTING CELL PROLIFERATION, AND METHOD FOR PREPARING CELL CLUSTER | 国立大学法人大阪大学 | 2021-01-14 | — | — | WO | disclosed |
| EP-2628481-B1 | Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV | ABBVIE BAHAMAS LTD (BS) | 2016-02-24 | — | — | EP | disclosed |
| US-20150218194-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-9006387-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2853531-A2 | Antiviral compounds | AbbVie Bahamas Ltd. (BS) | 2015-04-01 | — | — | EP | disclosed |
| EP-2455376-B1 | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) | ABBVIE BAHAMAS LTD (BS) | 2014-11-26 | — | — | EP | disclosed |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES | 2014-10-23 | — | — | US | disclosed |
| CN-101636081-B | Substituted phenylamidines and the use thereof as fungicides | BAYER CROPSCIENCE AG | 2014-09-03 | — | — | CN | disclosed |
| EP-2337781-B1 | ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION | ABBVIE BAHAMAS LTD (BS) | 2014-07-23 | — | — | EP | disclosed |
| EP-2368890-B9 | Hepatitis C virus inhibitors | ABBVIE BAHAMAS LTD (BS) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012007728-A2 | TOXOIDING METHOD | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2012-01-19 | — | — | WO | disclosed |
| EP-2368890-A1 | Hepatitis C virus inhibitors | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2337781-A2 | ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION | Abbott Laboratories (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144646-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100029013-A1 | Methods for Detecting Asymmetric Dimethylarginine in a Biological Sample | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-04 | — | — | US | disclosed |
| US-7611844-B2 | Methods for detecting asymmetric dimethylarginine in a biological sample | BOARD OF TRUSTEES OF THE LELAND STANFORD JR. UNIVERSITY (US) | 2009-11-03 | — | — | US | disclosed |
| US-20040214252-A1 | Methods for detecting asymmetric dimethylarginine in a biological sample | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-10-28 | — | — | US | disclosed |
| WO-2004046314-A2 | METHODS FOR DETECTING ASYMMETRIC DIMETHYLARGININE IN A BIOLOGICAL SAMPLE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2004-06-03 | — | — | WO | disclosed |
| WO-1989001333-A1 | IMIDAZO[1,2-b]PYRIDAZINES | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1989-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CES2 626/4885CES1 396/4885PRMT1 2863/4885 |
| US-20100029013-A1 | Methods for Detecting Asymmetric Dimethylarginine in a Biological Sample | ADM2, PADI3, PADI4 | CES2 955/4885CES1 460/4885PRMT1 8/4885 |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CES2 626/4885CES1 396/4885PRMT1 2863/4885 |
| US-20150218194-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CES2 626/4885CES1 396/4885PRMT1 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.